Back to News
Market Impact: 0.42
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
Source: seekingalpha.com
Healthcare & BiotechAnalyst InsightsCompany Fundamentals
Pharvaris maintained a Strong Buy rating after pivotal Phase 3 successes for both its on-demand and prophylactic hereditary angioedema (HAE) therapies. In the RAPIDe-3 trial, PHVS reported rapid symptom relief with a median time of 1.28 hours, supporting the clinical value proposition for its HAE pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
PHVS0.86
More News
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- How Pepsi fell behind in the cola wars—and then lost KFC
- 5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
- Braskem creditors, shareholders near deal on $11bn debt restructuring
- Xencor reports phase 1 data for cancer drug XmAb819
- The experience economy keeps defying expectations. Maybe we’ve been looking at it all wrong